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2D cell sheet technology with the aid of PNIPAAm temperature responsive changes on 
the hydrophobicity was already invented and widely applied as reviewed earlier. 
PNIPAAm caught much attention in recent years mainly because of its LCST of 32℃ , 
which is close to human body and cell culture temperature, and moreover, adjustable by 
adding in functional groups bearing different hydrophobicity during the polymerization 
procedure. 
 
The idea, development of 2D cell sheet technology into 3D in vivo cell culture instrument 
came from the high volume/space ratio 3D structure, especially PCL scaffolds, provided. 
In the research, the 3D exploration did not achieve as expected, partially due to the low 
crystallization point of PCL and limits in 3D grafting. PCL scaffolds did not withstand 
the last heat treatment step of the whole PNIPAAm chemical grafting process. 
 
However, the change of morphology and N% on 3D physically coated PCL scaffolds still 
indicates how different that a PNIPAAm layer may assist in cell culture, in vitro. Further 
investigations about 3D cell harvest can by done by selecting other scaffolds that may 
undergo the temperature required for 3D chemical grafting. 
 
Moreover, verified by the drop in water contact angle experiment, MTS assay, SEM 
result and confocal microscopy images, the PNIPAAm chemical grafting onto 2D PCL 
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films was well targeted and established. The 2D PNIPAAm grafted matrix greatly 
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Documentations about synthesis of poly(ε-caprolactone) (PCL) may be traced back as 
early as 1930s, in which the Carothers group reported and studied the ring-opening 
polymerization of ε-caprolactone (Fig. 1.1).1    
 
 




1.1.2 Physical and chemical properties 
 
PCL has the molecular weight ranging between 10,000 and 70,000 on average. It appears 
in a semi-crystalline form, insoluble at room temperature in alcohol, diethyl ether, and 
petroleum ether, but soluble in 2-nitropropane, benzene, chloroform, cyclohexanone, 
dichloromethane, and carbon tetrachloride. In solvents such as 2-butatnone, acetone, 
acetonitrile, dimethylformamide, and ethyl acetate, it shows a low solubility.  
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The glass transition temperature of PCL is 60 ℃.  The melting point of PCL varies from 
50 ℃ to 64 ℃, depending on its crystallinity2.  
 
When blended with cellulose propionate, polylactic acid, cellulose acetate butyrate, 
polylactic acid-co-glycolic acid, and other polymers, adhesion, dyeability, and crack 
resistance of polymer blends change2.  
 
PCL copolymers are formed by involving various monomers such as δ-valerlactone,  
chloroprene, diglycolide, diisocyanates, dilactide, ethyleneoxide, styrene, tetrahydrofuran, 
4-vinyl anisole, methyl methacrylate, polyethylene glycol, substituted caprolactones, and 
vinyl acetate.3
 
PCL is biodegradable. In the year of 20004 (ref), low MW PCL was implanted into rats 
and its biodegradation was studied. Radioactivity in experimental animals including 
faeces, urine, expired air, and implant site were measured. Results showed that the 
implant was absorbed completely within 60 days. This explained 60% of radioactivity 
observed whilst its original radioactivity maintained at the level of 9% on the 120th day 
onwards. Only ε-hydroxycaproic acid, due to hydrolysis in the implant, and tritiated 
water were detected as metabolites. Examining tissues under electron microscope, a 
group further found the presence of polymer particles in the intercellular space, and that 
phagocytosis played a role in polymer degradation in its final stage.4
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Due to its biocompatibility5,6,7, slow biodegradability, non-toxicity8,9, ability of forming 
blends, PCL has been extensively studied as a type of biomaterial, and manufactured into 
various forms such as films, scaffolds, microspheres and nanoparticles, with different 
applications, including drug delivery and bone graft substitute. 
  
1.1.3 Major biomedical applications of PCL 
 
1.1.3.1  Drug delivery system 
 
Many biodegradable polymers and their copolymers have been extensively studied to 
improve drug delivery, either in the form of microsphere or nanosphere. Polyesters 
including PCL, together with poly(lactide) and poly(glaycolide), are the most commonly 
studied for the purpose of drug delivery.10 
 
PCL is highly permeable to small molecules. It can be designed for long term delivery 
due to its slow degradability. Compared with poly(lactide) and poly(glycolide), PCL 
produces less acid into the environment during degradation, and blends well with other 
polymers.11
 
Various microsphere systems have been studied, by blending PCL with other polymers, 






Tabble 1.1 Fact sheet of microsphere based PCL or PCL blended 
 
Drug Delivered Component(s) Techniques Vitro/Vivo Researcher(s) 
PCL double emulsion both Jameela et al.12
PCL melt encapsulation both Jameela et al.13
PCL w/o/w solvent 
evaporation 
in vitro Youan et al.14
Antigen 
PLGA Spray-drying in vitro Murillo et al.15
Antihypertensive drugs PCL o/w or w/o/w emulsion In vitro Perez et al.16
Taxol PCL solvent 
evaporation 


















Colchicine PCL; PCL/PLA Entrapping; 
PEG coated 





PCL/PLA; PCL/cellulose acetate 
butyrate 
solvent evaporation In vitro Chang et al.21,22,23
Cyclosporine 
 
PCL solvent evaporation In vitro Aberturas et al.24
Cisplatin 
 
PCL/PLA solvent evaporation In vitro Chandy et al.25
E- and P-selectin PCL single emulsion In vitro Dickerson et al.26
Ribozymes PCL Injection of polymeric 
paste 
In vitro Jackson et al27
PCL solvent evaporation 
 







Bovine serum albumin 
PCL/poly(ethylene oxide)–
poly(propylene oxide) 
solvent evaporation In vitro Huatan et al.30
 PCL solvent evaporation In vitro Lin and Yu31; Lin 
et al.32
 PCL emulsion-solvent 
evaporation 
In vitro Lin and Huang33
Ethyl salicylate 
 
PCL solvent evaporation In vitro Gadzinowski et 
al.34
Nerve growth factor PCL; PCL/PLGA 
 






In vitro Bodmeier and 
Chen,36
Nitrofurantoin PCL solvent evaporation In vitro Dubernet et al.37
Insulin PCL solvent evaporation In vitro Shenoy et al.38
3,4-diaminopyridine PCL by different 
methods for 
In vitro Gibaud et al.39
 
Heparin PCL/poly(d,l-lactic-co-glycolic 
acid)/Eudragit RS and RL 
double emulsification; 
evaporation process 










 Several types of co-polymer microspheres were also found in documentation, which can 
be summarized into Table 1.2. 
 




Components Techniques Vitro/Vivo Researchers 
Steroids 
 




both Pitt et al.42; 
Buntner et al.43,44















































The major advantage of using nanosphere as delivery system lies in “selective targeting 
via reticuloendothelial system to liver and to cells that are active phagocytically”. Since 
1977, researchers have dwelt on this area by adopting PCL alone, or blended or co-
polymerized PCL. These studies, again can be classified into two groups, co-blending 










Components Techniques Vitro/Vivo Researchers 
Indomethacin PCL three submicron 
systems 


















In vitro Ferranti et al.56
Aceclofenac PCL Interfacial 
precipitation 
both Alonso et al.57
Diclofenac 
 

















Digitoxin PCL Interfacial 
precipitation 
both Guzman et al.68
Atovaquone PCL interfacial 
deposition 
In vitro Cauchetier et 
al.69






both Losa et al.71,72







PCL double emulsion 
pressure 
homogenization 














Components Techniques Vitro/Vivo Researchers 
Indomethacin 
 
































dialysis In vitro Ryu et al.79
 
 
1.1.3.2  Internal fixation 
 
Early in the 1980’s, PCL had been studied as the replacement of stainless steel for 
internal fixation. Various techniques were used to test its mechanical properties, with data 
obtained mostly from in vitro tests. Clinical trials had proven its applications for the 
internal fixation of bones, while fixation methods and designs remained two of the most 
important issues.80
 
1.1.3.3  Membrane implantation 
 
Besides bone implants, PCL has been processed into films as membrane implants. 
Ashammakhi et al (year) developed a poly(L-lactide/ε-caprolactone) (50/50, 0.4 mm 
thick) absorbable membrane and applied it on the dorsal neck of Wistar rats. Results 
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showed that this type of membrane is biocompatible. It cracked, fragmented, and 
progressively degraded within 28 months, though not completely. 81
 
1.1.3.4 Skin coverings for wounds 
 
When treated with biodegradable films, changes of coverings are not necessary during 
the whole recovery period, which is considered as one of the advantages of PCL films. 
 
The earliest evaluation of applying PCL as wound-covering material can be traced back 
to the year of 1977. That research was carried out by Schwope et al, both in vitro and in 
vivo, with three types of materials formed by PCL: 1) a freeze-dried collagen/PCL film 
laminate, 2) a freeze-dried PCL foam/PCL film laminate, and 3) a heat-dried 
collagen/PCL film laminate. Results showed that one graft was extremely adherent to 
wound (burned rat model) and most successful in promoting tissue bed formation.82
 
In the year of 1995, Jurgens’ group further tested other characters of PCL films for the 
purpose of its clinical application. No problems in terms of immunology or disease 
transmission were reported. Materials, as well as its degradation products, were proven to 
be non-toxic and suitable for cell culture (with keratinocytes). Although its permeability 
to bacteria changed as biodegradation continued, the material showed a secure protection 
for at least a medium term of 15 days. Clinical trials were then performed as the 
consequence of their results.83
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1.1.4 PCL scaffolds manufactured by fused deposition modelling (FDM) 
 
Recently, Teoh SH and co-workers successfully designed and fabricated a novel type of 
PCL scaffolds by FDM84, 85 method. By employing this method, scaffolds with a 
completely interconnected network and large interconnection channels were produced. 
Moreover, it offers a highly regular and reproducible scaffold morphology by computer 
controlled design and the fabrication guide. 
 
 
Figure 1.2 Brief illustration of the basic FDM process84
 
 
As illustrated in Fig. 1.284, the basic FDM process is composed of 4 steps. First, computer 
aided design (CAD) data is imported in STereoLithography (STL) format into software 
named Stratasys’ QuickSliceTM. After that, the CAD model is sliced into horizontal 
layers and conversed into the SLiCe (SLC) format. For each layer, a deposition path is 
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created and conversed into the Stratasys Machine Language (SML) format for loading 
into the FDM machine, which fabricates the actual physical part in the manner of layer by 
layer with a filament of PCL. 
 
With proper control of processing parameters, two patterns of PCL scaffolds were 
produced (Fig. 1.3 and Fig. 1.4). Their morphology, porosity, mechanical properties, as 
well as their in vitro and in vivo 85, 86, 87 behaviours were studied. Results further 
supported that these scaffolds are non-toxic, biocompatible, supportive and suitable for in 




Figure 1.3 (a) Lay-down pattern of 0º/90º/0º forming square honeycomb scaffolds. Its 






Figure 1.4 (a) Lay-down pattern of 0º/60º/120º forming square honeycomb scaffolds. Its 




1.2 Poly(N-isopropyl acrylamide) 
 
1.2.1 Historical perspective 
 
The first publication about Poly(N-isopropyl acrylamide) (PNIPAAm) appeared in 1956. 
Both synthesis and polymerization process were included in the article, and PNIPAAm 
was descript as water repellent (Fig. 1.5).88,89,90  Since then studies on PNIPAAm have 
increased rapidly and sharply91. 
 
        
 
Figure 1.5 Structure of monomer N-isopropyl acrylamide and polymer PNIPAAm 
 
 
Appearing as white crystal power, PNIPAAm can be synthesized by various methods 
including radiation, ionic, redox , and free radical polymerization in organic solutions or 
aqueous media. 
 
1.2.2 Physical and chemical properties 
 
The interactions among the segments of a polymer and surrounding molecules determine 
the alignment and behavior of the polymer. PNIPAAm follows the same rule.  When 
dissolved in water, it has the ability of shifting from hydrophilic to hydrophobic as 
temperature increases, offering positive free energy change (△G). The temperature 
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resulting in the phase separation is addressed as lower critical solution temperature 
(LCST). 
 
PNIPAAm has the LCST of 32℃ in water under the normal air pressure. When 
connected to different co-monomers in the synthesis process,  PNIPAAm co-polymers 
show various functions and may form gels. 
 
1.2.3 Major biomedical applications of PNIPAAm 
 
The precipitation and hydrophilic-hydrophobic transition characters were mostly studied 
in recent years. Amongst all the researchers, Hoffman’s and Okano’s groups have made 
successful progress. 
 
1.2.3.1 Phase separation and “molecule gate” 
 
A variety of polymer-conjugated biomolecule can be created by conjugation of the 
biomolecule to proteins and oligopeptides, sugars and polysaccharides, single and 
double-stranded oligonucleotides and DNA plasmids, simple lipids and phospholipids, 
and a wide spectrum of recognition ligands and synthetic drug molecules (Fig. 16). In 
these studies, PNIPAAm was either randomly or site-specifically conjugated.92
 
As discussed previously, the LCST of PNIPAAm is 32℃, exhibiting the solubility if 
temperature is below 32℃, and quick precipitation if solution heated beyond that 
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temperature. When NIPAAm copolymerized with more hydrophilic or hydrophobic 
monomers, acrylamide and n-butyl acrylamide separately for example, this LCST may be 
adjusted either higher or lower (Fig. 1.7).92  As shown in the illustration, proteins can be 
conjugated randomly to form different oligomers (Fig. 1.8).  In the study, chain-transfer 
free-radical polymerization was introduced to form the functional group on one end of 
oligomers.93  In random conjugation, lysine amino, -COOH in aspartic and glutamic acid, 
or -OH in cysteine residues offers reactive sites for proteins.94
 
Due to their thermal triggered precipitation, these PNIPAAm-protein bioconjugates are 
used for selection of specific enzymes from enzyme solution. An illustration has been 
cited below.95,96,97 Moreover, if this bioconjugate shows affinity to other molecules, a 
complex may form in solution and precipitate as temperature increases. This phenomenon 
can be used for phase separation and selection of certain molecules that might attach to 






Figure 1.6 Schematic illustration of the variety of natural or synthetic biomolecules 
which may be conjugated to a smart polymer. In some cases, only one molecule may be 
conjugated, such as a recognition protein, which may be linked to the protein at a reactive 
terminal group of the polymer, or it may be linked at a reactive pendant group along the 
polymer backbone. In other cases more than one molecule may be conjugated along the 





Figure 1.7 Copolymerization of a thermally sensitive polymer, PNIPAAm, with a more 
hydrophilic comonomer, AAm, raises the LCST of the copolymer, while 
copolymerization with a more hydrophobic comonomer, N-test butylacrylamide (N-




Figure 1.8 Various types of random and site-specific smart polymer-protein conjugates. 
In the latter case, conjugation near the active site of the protein is intended to provide 
stimulus control of the recognition process of the protein for its ligand, while conjugation 







Figure 1.9 Schematic illustration of the stimuli-induced phase-separation of a random 
conjugate of a smart polymer and a ligand that is complexed with a recognition protein. 
This is essentially an affinity chromatography process carried out in solution. It may be 
used to selectively separate a specific molecule for its recovery, assay, or removal (if it is 
a toxin or pollutant). Recognition proteins include antibodies, avidin, streptavidin, Protein 
A, Protein G, cell membrane receptors (e.g., integrins), and many others.1–3. The process 
may be used in “reverse” and a recognition ligand (e.g., biotin) may be attached to the 





Figure 1.10 (a) Schematic illustration of the stimuli-induced phase-separation of a 
random conjugate of a smart polymer and a recognition protein coupled to a specific 
analyte which is coupled to a second, labeled recognition protein, to form a smart 
polymer-immune complex sandwich conjugate. This process is essentially an 
immunoassay such as ELISA (enzyme- linked immunosorbant assay) carried out in 
solution. 1–3 (b) Schematic illustration of the same process carried out with one test 
sample, in order to assay two separate analytes in the same sample by using two different 
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smart polymers having different LCSTs (e.g., see Fig. 3). This two step process may use 
two temperature-sensitive polymers, two pH-sensitive polymers, or one of each.92
Compared with random conjugation, site specific conjugation is only practical to proteins, 
of which the full sequences have been known. In the process, a specific amino acid is 
inserted for reaction on the selected site of the protein, which is produced according to 
genetically engineering DNA sequences via cell culture. –SH and -NH2 have been 




Figure 1.11 Schematic of the process for preparing a site specific conjugate of a smart 
polymer with a genetically engineered mutant protein.92
 
 
By conjugation of a cysteine residue to a mutant cytochrome-b5 far from the latter’s 
active binding position, and PNIPAAm onto the thiol group of the cysteine, a site specific 
PNIPAAm-bioconjugate may be created. During the precipitation triggered by thermal 
changes, this conjugate has been proven to assure a minimal loss of protein activity, 






Figure 1.12 Schematic illustration of the stimuli-induced phase-separation of a random 
conjugate of a smart polymer and an enzyme. This general process should be useful for 
the removal of any specific molecule from a complex mixture for the purpose of recovery 
and possible recycling of that molecule.99
 
 
When inserted to a position near the binding active site of a protein, the PNIPAAm acts 
as a “molecule gate”, unblocking or blocking the active site when the temperature is 
lower or higher then the LCST. The streptavidin (SA) was selected as the protein for 
PNIPAAm insertion. Further research indicates that a molecule with of PNIPAAm(co-
polymers) plays an important role in efficiently “gating” the active site of SA. This 






















Figure 1.13 Schematic illustration of the “gating” and “switching” possibilities for a site-
specific conjugate of a smart polymer and a mutant recognition protein.103, 105,106
 
 
1.2.3.2 Two dimensional cell sheet technology 
 
The 2D cell sheet technology allows cells to detach rapidly from their culture surface 
with minimal loss of their functions.  This is caused by the transition of PNIPAAm layer 
from hydrophobic to hydrophilic states, when cell cultures are shifted from 37 ℃, which 
is the normal culture temperature, to room temperature (Fig. 1.14). This technology is 
especially helpful in harvesting cardiac cells beating at the same rate and endothelial cell 
sheets for repair of vessels. 
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Sandwich cell culture layers can be formed when a PNIPAAm layer is inserted in 
between the tissue culture grade polystyrene (TCP) and another fibronectin (FN) cell 




Figure 1.14 Schematic diagrams for possible interactions of materials surfaces with cells. 










Alternatively, PNIPAAm grafted by electron beam irradiation onto the surface of porous 
membranes also supports the temperature-controlled cell sheet detachment within 30 
minutes, compared 75 minutes on PNIPAAm grafted TCPs.108 Accelerated cell sheet 
harvests are further successfully found by co-grafting PNIPAAm with PEG onto porous 





Figure 1.16 Cell sheet engineering using PIPAAm-grafted surfaces. (a) Schematic 
illustration for temperature-induced recovery of intact monolayer cultures. (b) Confluent 
culture of endothelial cells on PIPAAm-grafted dishes at 37.8C. (c) Detaching 


















Figure 1.17 An illustration of cell sheet detachment by different types of water supply to 




1.2.3.3 Polymeric carriers 
 
Besides applications for immunoassay and cell sheet harvest, PNIPAAm has been 
extensively studied as micro- and nano- sized carriers for drug delivery, as the LCST of 
its copolymers can be adjusted close to human body temperature of 37℃ by adding in 
more hydrophilic monomers as discussed earlier. 
 
Among all these studies, several different methods have been developed for PNIPAAm 
delivery device (Tab. 1.5). Two of them (“process 1” and “process 3”) rely on diffusion 
to form PNIPAAm gel carriers, one (“process 2”) takes advantage of the pressure 
generated to squeeze drugs out during the phase of gel collapse, leaving much less studies 
involved with the fourth method (“process 4”) (Fig. 1.17).110
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Table 1.5 Various schemes of drug delivery with PNIPAAM gels110
 
Methods Loading Release 
Process 1 Temperature < LCST Temperature < LCST 
Process 2 Temperature < LCST  Temperature > LCST 
Process 3 Dried  Temperature > LCST 







Figure 1.18 Various schemes for PNIPAAM in drug delivery.110
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2. Materials and methods 
 
Figure 2.1 A flow chart of applications of PNIPAAm onto PCL materials 
 
2.1. Physical coating of PNIPAAm onto PCL scaffolds 
2.1.1. Materials 
 
PNIPAAm purchased from Merck & Co. Inc. was kindly provided by Dr. Tong Yen Wah 
from the National University of Singapore. Isopropyl alcohol, and 24 well assay plates 
were purchased respectively from Merck, and NUNC. Ethanol was purchased from 
Aldrich and used as received. 
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 Fibroblast cells were kindly provided by Dr. Li Jun. Dulbecco's modified eagle medium 
MEM), fetal bovine serum (FBS) and penicillin-streptomycin (PS) were purchased 
CL scaffolds (50×50×3 mm) were cut into discs with diameter of 
5mm and then placed into a 24 well assay plate and then immersed in 70% ethanol over 
 
 under room temperature 
nd shifted to another 24 well assay plate to remove unattached PNIPAAm. These 
 at 37 
.2.1. 3D grafting of PNIPAAm onto PCL scaffolds 
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from Invitrogen (Green Island, NY, USA) respectively, and used as received to prepare 




Four samples of P
1
night for sterilization. PNIPAAm was dissolved in isopropyl alcohol solution for the
coating solution concentrated 1M to replace the 70% ethanol.  
 
Samples immersed in 1M coating solution were then vacuumed
a
samples were added with 0.5 ml per well of DMEM cell culture medium before 
incubation (Forma Air Jacketed Co2 Incubat, Thermo Farma, Marietta, Ohio, USA)
℃, 5% CO2 and 100% humidity overnight. 
 





NIPAAm monomer, hexane, APS and medical grade were purchased from Sigma Aldrich 
t. Louis, Missouri, USA). Both hexane and APS solution were used as received. 
lved 




folds sterile ultra sharp Gillette Super 





2.2.1.2.  Preparation of purified NIPAAm and polymerization solution 
 
NIPAAm was purified with hexane. Briefly, NIPAAm monomer powder was disso
in
procedure was repeated three times to remove impurities that might affect polymerization
reaction. Purified NIPAAm was further dissolved in DI H2O at the concentration o




PCL scaf were cut into (3×3×2) mm cube by a 
N
groups as control and sample, which were immersed, at 60℃ for 2 hours with 1 mg/m
APS, in DI H2O and polymerization solution, respectively.. For the step of plasma 
treatment, PCL cubes were inserted into the equipment chamber.  
 




NIPAAm monomer, hexane, APS and PCL pellets (MW: 65,000) were purchased from 
ycin 
.2.2.2. Methods 
. on of purified NIPAAm and polymerization solution 
IPAAm was purified by treatment with hexane. Briefly NIPAAm monomer powders 
on 
 (wt) 
.2.2.2.2. Preparation of PCL films 
eat press method was adopted to produce PCL films. One PCL pellet was placed on one 
Sigma, Biorad and Osteopore International, respectively. Both hexane and APS solution 
were used as received. L-929 cell line was purchased from the ATCC.  Dulbecco's 
modified eagle medium (DMEM), fetal bovine serum (FBS) and penicillin-streptom
(PS) were purchased from Invitrogen separately and used as received to prepare the 






were dissolved in hexane at 50~60℃, precipitated, and vacuum dried at room 
temperature for three times to remove impurities that might affect polymerizati
reaction. Purified NIPAAm was further dissolved in DI at the concentration of 20%






piece of glass slide, covered by another, heated to 65℃, and pressed by a heavy object of 
2 kg for 20 minutes. Films formed in between the two slides were then immersed in DI 
 27
H2O for 5 hours for detachment, freeze-dried overnight and punched by a brand new 
puncher to produce small round pieces of samples. 
 
2.2.2.2.3. Plasma treatment 
 
PCL samples were inserted into the chamber, experienced a period of 60 seconds under 
10 Pa at 30 W. The carrier for plasma treated PCL scaffolds was also placed together and 
subjected through the same process to exclude interference from the carrier for U.V. 
polymerization. 
 
2.2.2.2.4. U.V. polymerization 
 
During the transportation, the PCL samples were kept in a nitrogen gas, filled and well-
sealed in a 24 well assay plate after plasma treatment. These samples were then immersed 
in the 20% (wt%) NIPAAm solution prepared with DI H2O, and pure DI H2O, 
respectively. A small amount of APS at 1mg/ml was added into the NIPAAm solution. 
All immersed samples were then exposed to ultra violet light of 293nm for 15~20 
minutes by a Vilber Lourmet TFX-20LC system with cooling fans. 
2.2.2.2.5. Water contact angle measurements  
 
After U.V. irradiation, two groups of samples were washed with DI H2O over night and 
freeze dried. Water contact angles of the two groups were measured by using Rame-hart, 
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Inc. (Netcong, New Jersey, USA) Automated Contact Angle Geniometer and RHI 2001 
Imaging Surface system. This was done at room temperature and 60% relative humidity. 
 
2.2.2.2.6. Cell seeding and culture 
 
Freeze dried samples were immersed in 70% (vol%) ethanol solution for 4 hours, placed 
into a 96 assay plate, and exposed at room temperature overnight for sterilization. L-929 
cells were cultured in DMEM with 10% FBS and 1% PS added, in a self-sterilizable 
incubator (Thermo Forma Direct Heat Incubator U-LH100HG) at 37℃ with 5% CO2, 
95% air, and 99% relative humidity. These cells were seeded onto PCL film samples 
during their logarithmic growth phase, at the density of 105 cells per well in 200 μl of 
culture medium. The 96 well assay plates that were seeded with cells were returned to the 
same incubator for two days before further experiments. 
 
2.2.2.2.7. 3-(4.5-Dimethythiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium compound (MTS) assay for acute cytotoxicity analysis 
 
L-929 cells were tested by by CellTitrer 96 Aqueous Non-Radioactive Cell Proliferation 
Assay with kit purchased from Promega (Madison, Wisconsin, USA). Briefly, a stock 
solution of PMS (mg/ml in PBS) was diluted 1/20 in MTS (2mg/ml in DMEM, pH 6.7). 
The MTS/PMS mixture was further diluted 1/5 (v/v) in basal medium and added to 96-
well culture plates. After incubation for 4 hours at 37℃, absorbance was measured at 492 
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nm and a percentage maximal proliferation calculated as an absorbance ratio of sample 
wells to wells containing control (non-glycosylated) bFGF.  
 
2.2.2.2.8. Confocal laser scanning microscopy (CLSM) 
 
After two days of culture, seeded samples was rinsed at 37℃ with prewarmed PBS and 
stained by green fluorescent mitotracker green FM. The original cell culture medium 
(DMEM with 20% FBS and 1% PS) was replaced with 37℃ prewarmed staining 
solutions, which refers to DMEM containing 50nM green fluorescent mitotracker green 
FM, 20% FBS, and 1% PS. The 96 well assay plate was then returned to the self 
sterilizable incubator for 45 minutes of 37℃ with 5% CO2, 95% air, and 99% relative 
humidity. Then the staining solution was replaced with fresh prewarmed normal culture 
medium, and samples were observed using a research inverted microscope Olympus U-
LH100HG fluorescence microscope fitted with the correct filter set. 
 
2.2.2.2.9. Scanning electron microscopy (SEM) 
 
Cell and film morphology were studied by SEM. Samples were fixed in 2.5% 
glutaraldehyde for 20 minutes, and dehydrated with 5 minute immersion each in ethanol 
solution at 30%, 50%, 70%, 90%, 95%, 100%, and 100% each. Treated samples were 
then freeze-dried. Samples were gold coated for 20 seconds before observation by 
electron microscopy. 
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 3. Results and Discussion 
3.1. Physical coating of PNIPAAm onto PCL scaffolds 
 
Fibroblast cells were seeded on physically coated PCL scaffolds at 37℃ and inspected 
under microscope after 24hours. Cells have attached to the PCL scaffolds in 24 well 
plates. 
 
Scanning electron microscopy photos revealed a different surface morphology of 
PNIPAAm coated PCL scaffolds samples (Fig. 3.1) compared with control group (Fig. 
3.2). The uneven surface may be caused by the physical coating. 
 
X-ray photoelectron spectroscopy results indicated the difference in percentage of 
nitrogen element on the samples and control. As PCL doesn’t contain nitrogen content, it 
is suspected this difference was the result of coating of PNIPAAm polymers (Fig. 3.3). 
 
These samples were kept at 37℃ for another two days and inspected again under 
microscope at room temperature. After 5 minutes at room temperature, no cells were 
found attached to PCL scaffolds. 
 
The commercial PCL scaffolds had been proven safe and non-toxic for cell culture 
purpose in previous research done by others84.  It was observed under the optic 
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microscope, on the second day of cell seeding, that the seeding on coated PCL scaffolds 
was successful, compared with the control group, on which almost no cells attached. 
 
This observation might indicate the PNIPAAm coat changed the surface characteristic 
and thus turned the PCL scaffold into being affiliated to cell attachment, whilst the SEM 
and XPS results both support the indication. 
 
Moreover, because the PNIPAAm was merely physically coated onto the scaffold 
samples, and it switched from hydrophobic to hydrophilic when temperature was lowered 
below its LCST of 32℃, chances are that the PNIPAAm coated dissolved after the 24 
well cell culture plate exposed to room temperature for 5 min. Hence cells left the 
scaffolds at the same time. 
 
 
Figure 3.1 A picture of PCL scaffolds samples placed in 24 well plates after physical 
coating for further cell seeding. 
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Figure 3.3 XPS result of (a) control group with 70% ethanol as reaction agent after 
plasma treatment. (b) sample group with PNIPAAm dissolved in 70% ethanol as 
reaction agent after plasma treatment. 
a b 
a b 
Figure 3.2 SEM result of (a) control group with pure isopropyl alcohol as reaction 
agent after plasma treatment. (b) sample group with PNIPAAm dissolved in pure 
isopropyl alcohol as reaction agent after plasma treatment. The difference between the 





3.2. Chemical grafting of PNIPAAm 
3.2.1. 3D grafting of PNIPAAm onto PCL scaffolds 
 
According to methods used by other researchers, chemically grafted samples are 
supposed to be washed in DI water and then immersed overnight to clean NIPAAm 
residues after heat treatment. 
 
But after going through heat treatment at 65 or 37 Celsius, PCL scaffolds deformed and 
melted, which is detectable by the naked eye. These 3D chemical grafting steps were 
repeated three times, and each time PCL scaffolds did not withstand the heating process, 
possibly due to the low crystallization point of the PCL scaffolds. 
 
3.2.2. 2D grafting of PNIPAAm onto PCL films 
 
Water contact angle of PCL films without and with PNIPAAm grafting was tested.  Fig. 
3.4 shows a higher hydrophilicity on the sample group, probably due to the impact of 
PNIPAAm grafting, which is hydrophilic at room temperature, as PCL surface remains 
highly hydrophobic.  
 
Scanning electron microscopy images were taken to study cell attachment on PNIPAAm 
grafted PCL films (Fig. 3.5). The control group, without PNIPAAm grafting showed a 
smooth surface while rough surfaces with traces of cell attachment were demonstrated in 
the sample group.  
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Under confocal microscopy, again, the sample group suggests that the cells were alive, 
compared with the blank in control group. L929 cells, both at the central and the edge of 
the PCL film was represented, further indicating the impact of PNIPAAm grafting on the 
PCL films. 
 
To further investigate the status of cells growing on these two groups, cell viability assay 
using MTS was performed. Results implied higher cell viability on the sample group by a 
higher absorbance, which increased with cell seeding density (Fig. 3.6). 
 
Supported by data and images above, it was likely the PNIPAAm layer grafted that 
changed the morphology, character, and cell attachablity of PCL surface. When placed at 
room temperature, cells did not start detachment until 20 minutes later (Fig. 3.7), leaving 
a layer of cell sheet floating in the culture medium. 
 
 Figure 3.4 Water contact angle measurement result of control group and sample 





    
a b c
   
d ae f
   
 Figure 3.5 SEM result of (a) control group, and (b)&(c) sample group, PNIPAAm 
grafted.  And Representative confocal microscopy of cell morphology of (d) control 
group, and (e)&(f) sample group. (e) demonstrated the central part and (f) revealed 







Control (cell seeding density: 2.5×105cells/ml) and 3 Groups of Samples 






2H-tetrazolium compound assay of L929 cell viability based on different seeding densities 
(1×105, 2.5×105, and 5×105 cells/ml). Statistical analysis revealed cells showed higher 
absorbance as density increases. Abbreviation: OD, optical density. 
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 Figure 3.7 Pictures of cell sheet detached from PCL film, sample group, left on the 




















 4. Conclusion 
 
Poly(ε-caprolactone) (PCL), due to its unique biodegradability, has been mainly studied 
in the form of film and scaffold for potential in vivo application in the biomedical 
engineering fields. Poly(N-isopropyl acrylamide) (PNIPAAm), as one of the most 
popular thermo-sensitive polymers, has been recently practised in temperature-controlled 
cell release107,108,109,110. 
 
The idea of developing thermo-sensitive cell releasing matrix was proposed considering 
the attractive surface to volume ratio brought about by poly 3D poly(ε-caprolactone) 
scaffolds in the process of in vitro cell culture, and the convenience to treat it when 
unwanted. Both physical coating and chemical grafting methods were adopted to study its 
characters. 
 
In this project, the physical coating of PNIPAAm onto 3D PCL scaffolds was successful, 
confirmed and verified by both the SEM and XPS tests, whereas the 3D chemical 
grafting of PNIPAAm did not fulfil expectations, partially due to the low crystallization 
point of PCL and limits in 3D grafting procedures. However, the PNIPAAm chemical 
grafting onto 2D PCL films was well-achieved, as proven and confirmed by the drop in 
water contact angle experiment, MTS assay, SEM result and confocal microscopy images. 
Due to the lack of cytotoxicity of PCL, the 2D PNIPAAm-grafted matrix may be deemed 
to fully support cell attachment and growth. 
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 Further investigations on the 3D cell harvest can be done by selecting other scaffolds that 
may undergo the temperature required for 3D chemical grafting. If possible, a non-
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